The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 50.70
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.20 (0.398%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 50.70
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Share buyback programme

18 Dec 2023 07:00

RNS Number : 0631X
IP Group PLC
18 December 2023
 

FOR RELEASE ON

18 December 2023

 

 

IP Group plc - Share buyback programme

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group" or "the Company"), which invests in breakthrough science and innovation companies with the potential to create a better future for all, announces that it has today launched a share buyback.

In light of the prevailing discount between the Company's share price and its NAV per share, the Board has determined that now is an appropriate time, consistent with its commitment to shareholder returns, to initiate a share buyback of up to £20 million (the "Buyback Programme").

 

The Directors believe the current share price discount to NAV significantly undervalues IP Group's portfolio. They have therefore determined to allocate a proportion of cash realisations to shareholder returns through the Buyback Programme. As at 30 November 2023, IP Group had achieved cash realisations of £38 million and had gross cash of £235 million.

 

The Board remains committed to making regular cash returns to shareholders from realisations. In future these regular cash returns will normally be made in the form of share buybacks when the share price discount to NAV exceeds 20%. Regular dividend payments will be suspended under such conditions, including consideration of any final dividend for 2023.

 

Details of the Buyback Programme

 

IP Group has entered into a non-discretionary arrangement with Deutsche Numis to manage the Buyback Programme on its behalf under which the Group will repurchase ordinary shares of 2 pence each in IP Group ("Ordinary Shares") up to an aggregate consideration of £20.0 million. This will be done within certain parameters, including to only buy back Ordinary Shares at a greater than 20% discount to the most recently announced NAV per share. The Buyback Programme will run from the date of this announcement until the end of 2024 unless completed or terminated earlier. Deutsche Numis will make its trading decisions in relation to the Ordinary Shares independently of the Group. 

Purchases of Ordinary Shares pursuant to the Buyback Programme will take place in open market transactions and may be made from time-to-time depending on market conditions, the Group's share price, trading volumes in the Group's Ordinary Shares and other factors. The maximum price paid per Ordinary Share (exclusive of expenses) will be no more than the higher of: (i) 5 per cent above the average of the middle market quotations taken from the London Stock Exchange Daily Official List for the five business days preceding any Ordinary Shares being purchased; and (ii) the higher of the price of the last independent trade and the highest independent bid for Ordinary Shares on the trading venue where the purchase is carried out. The minimum price shall be no less than (exclusive of expenses) a price of 2 pence per Ordinary Share, being the nominal value of an Ordinary Share. Under the Buyback Programme, any Ordinary Shares purchased will be held in treasury.

The Buyback Programme is in accordance with IP Group's general authority to purchase a maximum of 103,677,065 Ordinary Shares, granted by its shareholders at the Annual General Meeting held on 15 June 2023. The Buyback Programme will also be effected within the parameters of the Market Abuse Regulation 596/2014/EU and the Commission Delegated Regulation 2016/1052/EU (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), including where relevant pursuant to the Market Abuse (Amendment)(EU Exit) Regulations 2019), and in accordance with Chapter 12 of the Financial Conduct Authority's Listing Rules. IP Group confirms that it is not in a closed period and currently has no other unpublished price sensitive information.

IP Group will make further regulatory announcements to shareholders in respect of purchases of Ordinary Shares by the Group as they occur.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Vic Wallin

Alex Donaldson

+44 (0) 7973 823119

+44 (0) 7516 729702

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. Athe most active UK based, early stage science investorwe develop and support some of the world's most exciting businesses in deeptech, life sciences and cleantech (led by Kiko Ventures). Through Parkwalk, the UK's largest growth EIS fund manager, we also back world-changing innovation emerging in leading universities and research institutionsOur specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO. For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCVDLBFXLLLFBE
Date   Source Headline
2nd Dec 202211:38 amRNSPortfolio company funding leads to £36m gain
30th Nov 202210:41 amRNSTotal Voting Rights
21st Nov 20222:13 pmRNSLife sciences presentation postponed
2nd Nov 20223:51 pmRNSInvestor presentation on life sciences
1st Nov 20228:59 amRNSNotification of major holdings
31st Oct 20224:35 pmRNSDirector/PDMR Shareholding
27th Oct 20224:55 pmRNSPDMR Dealing – SAYE Exercise
24th Oct 20226:02 pmRNSHolding(s) in Company
14th Oct 20229:42 amRNSHolding(s) in Company
30th Sep 202210:39 amRNSTotal Voting Rights
21st Sep 20225:29 pmRNSHolding(s) in Company
20th Sep 20226:10 pmRNSDirector/PDMR Shareholding
15th Sep 20224:41 pmRNSInvestor presentation
14th Sep 20224:33 pmRNSFurther re Scrip Dividend
13th Sep 20226:00 pmRNSFurther re Interim Scrip Dividend
13th Sep 20227:01 amEQSIP Group Trust (IPO): Initiation — International investor in impactful innovation
7th Sep 20224:33 pmRNSDirector/PDMR Shareholding, SAYE scheme
31st Aug 20228:51 amRNSIstesso starts Phase 2b trial of MBS2320
30th Aug 202212:59 pmRNSCash acquisition of portfolio company Diurnal
18th Aug 20229:25 amRNSScrip Dividend Reference Price
11th Aug 202210:50 amRNSHolding(s) in Company
3rd Aug 20227:00 amRNSHalf-yearly results
2nd Aug 20227:00 amRNSPortfolio company Hysata completes funding round
13th Jul 20229:30 amRNSNotice of Results
30th Jun 20225:46 pmRNSRSP awards and Scrip Elections
29th Jun 20229:16 amRNSFurther re Scrip Dividend
22nd Jun 20227:00 amRNSLaunches ‘Kiko Ventures’ cleantech platform
16th Jun 202211:27 amRNSDirector/PDMR Shareholding
14th Jun 20227:00 amRNSAGM Statement
8th Jun 20227:30 amRNSTR-1
6th Jun 20228:14 amRNSScrip Dividend Reference Price
1st Jun 20223:23 pmRNSInvestor presentation; AGM arrangements
13th May 202212:43 pmRNSDirector Declaration
9th May 20225:21 pmRNSNotice of AGM, Annual Report
29th Apr 20223:46 pmRNSTotal Voting Rights
27th Apr 20226:16 pmRNSDirector/PDMR Shareholding
25th Apr 20226:09 pmRNSDBSP awards; Director/PDMR shareholding
5th Apr 20227:00 amRNSPortfolio company First Light achieves fusion
16th Mar 20227:00 amRNSAnnual Results
7th Mar 20228:00 amRNSPortfolio co Microbiotica completes £50m raise
2nd Mar 20229:19 amRNSNotice of Results
14th Feb 20227:00 amRNSPortfolio company Bramble raises £35m
14th Feb 20227:00 amRNSPortfolio co First Light completes $45m fund raise
28th Jan 20225:02 pmRNSTransaction in Own Shares
28th Jan 20227:00 amRNSTransaction in Own Shares
27th Jan 20227:00 amRNSTransaction in Own Shares
25th Jan 20225:45 pmRNSHolding(s) in Company
25th Jan 20225:39 pmRNSTransaction in Own Shares
24th Jan 20225:58 pmRNSTransaction in Own Shares
24th Jan 20227:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.